Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-01
2008-12-16
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040, C514S235500, C514S218000, C514S217040, C514S278000, C514S300000, C514S265100, C546S113000, C546S015000, C546S117000, C540S597000, C540S575000, C544S127000, C544S061000, C544S280000
Reexamination Certificate
active
07465726
ABSTRACT:
Compounds represented by Formula (I):or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
REFERENCES:
patent: 5877178 (1999-03-01), Gangjee
patent: 5958930 (1999-09-01), Gangjee
patent: 6140317 (2000-10-01), Traxler
patent: 6140332 (2000-10-01), Traxler
patent: 6180636 (2001-01-01), Traxler
patent: 6180643 (2001-01-01), Zablocki
patent: 6187778 (2001-02-01), Dow
patent: 6232320 (2001-05-01), Stewart
patent: 6479507 (2002-11-01), Cheng
patent: 6537999 (2003-03-01), Gangjee
patent: 6541481 (2003-04-01), Kath
patent: 6579882 (2003-06-01), Stewart
patent: 6610847 (2003-08-01), Blumenkopf
patent: 6635762 (2003-10-01), Blumenkopf
patent: 6673802 (2004-01-01), Castelhano
patent: 6680324 (2004-01-01), Castelhano
patent: 6696455 (2004-02-01), Gangjee
patent: 6686366 (2004-03-01), Castelhano
patent: 6713474 (2004-03-01), Hirst
patent: 6939874 (2005-09-01), Harmange
patent: 7115617 (2006-10-01), Buchanan
patent: 7244733 (2007-07-01), Hunt
patent: 7259154 (2007-08-01), Cox
patent: 7301023 (2007-11-01), Flanagan
patent: 7326699 (2008-02-01), Capraro
patent: 7335667 (2008-02-01), Rodgers
patent: 2003/0036545 (2003-02-01), Castelhano
patent: 2003/0125343 (2003-07-01), Gambacorti-Passerini
patent: 2003/0199525 (2003-10-01), Hirst
patent: 2004/0138238 (2004-07-01), Dhanoa
patent: 2004/0214820 (2004-10-01), Kleeman
patent: 2005/0171128 (2005-08-01), Blumenkopf
patent: 2005/0250119 (2005-11-01), Taing
patent: 2005/0256140 (2005-11-01), Luke
patent: 2005/0267304 (2005-12-01), Cox
patent: 2006/0142330 (2006-06-01), Bernotas
patent: 2006/0148831 (2006-07-01), Bernotas
patent: 2006/0270665 (2006-11-01), Wood
patent: WO 97/28161 (1997-08-01), None
patent: WO 98/43973 (1998-10-01), None
patent: WO 99/62908 (1999-12-01), None
patent: WO 01/72751 (2001-10-01), None
Peng, T. et al (2003) J. Chem.Inf.Comput.Sci.:43:298-303.
International Preliminary, date of issue, Feb. 6, 2007, Report I on Patentability in PCT/US2005/27274.
International Preliminary, date of issue, Mar. 1, 2006, Report II on Patentability in PCT/US2005/27274.
Written Opinion of the International Search Authority in PCT/US2005/27274.
International Search Report in PCT/US2005/27274, date of mailing, Oct. 20, 2006.
Ahmed Saleh
Barba Oscar
Bloxham Jason
Cox Matthew
Dawson Graham
Coleman Brenda L.
Moore Susanna
OSI Pharmaceuticals, Inc.
LandOfFree
Substituted pyrrolo[2.3-B]pyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrrolo[2.3-B]pyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolo[2.3-B]pyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028051